Pegulicianine clinical trials
Also written LUM015.
How each study uses pegulicianine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegulicianine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Apr 2024 · LUMISIGHT · NDA 214511 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2012 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Lumicell, Inc. (3) · Massachusetts General Hospital (2) · David Kirsch (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pegulicianine.
- Feb 2027Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersPhase 1/2 · Lumicell, Inc.
Studies
Open first, then newest update. How each study uses pegulicianine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study to Determine the Clinical Significance of Intravascular OCT-NIRAFEnrolling by invitationNot applicableMassachusetts General HospitalNCT06374498Written as LUMISIGHT Injection
- Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery PlaquesNot yet recruitingEarly Phase 1Massachusetts General HospitalNCT06957821Written as Pegulicianine
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersActive, not recruitingPhase 1/2Lumicell, Inc.NCT02584244Written as LUM015
- Investigation of Novel Surgical Imaging for Tumor ExcisionCompletedPhase 3Lumicell, Inc.NCT03686215Written as Study Device Arm
- Feasibility Study of Intraoperative Imaging in Breast CancerCompletedPhase 1/2Lumicell, Inc.NCT02438358Written as LUM015
- Cathepsin Activatable Fluorescent ProbeCompletedPhase 1David KirschNCT01626066Written as LUM015
Given beside what is tested · 1 — pegulicianine is usual care or a partner of the new treatment
Codes
What other systems call pegulicianine · ClinicalTrials.gg INT002175
- MeSH (NLM) C000731949pegulicianineOne source NLM
- UNII (FDA) T6HE85WN0QPEGULICIANINEConfirmed FDA, NLM
- NCI Thesaurus C175838PegulicianineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731949 | pegulicianine | One source NLM |
| UNII (FDA) | T6HE85WN0Q | PEGULICIANINE | Confirmed FDA, NLM |
| NCI Thesaurus | C175838 | Pegulicianine | One source FDA |
Also registered as pegulicianine acetate (UNII F3F6208UMT).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.